Affiliation:
1. Sechenov First Moscow State Medical University (Sechenov University)
Abstract
The skin, as an organ in combination with a large number of commensal bacteria that colonized its surface and hair follicles, should be considered as a full-fledged and complex ecosystem. The imbalance of the skin microbiome can lead to skin diseases. The proportion of pyoderma among all skin pathology ranges from 17 to 36% among the population of the Russian Federation. Most skin infections occur de novo, but pyoderma often occurs when exposed to predisposing factors (for example, a violation of the skin barrier, the presence of maceration, old age, diabetes mellitus, obesity, peripheral arteriovenous insufficiency, corticosteroid treatment or chemotherapy, dysglobulinemia, blood diseases, cachexia, congenital or acquired immunodeficiency). Staphylococcus aureus and Streptococcus spp. they are the cause of most pyoderma. In patients undergoing long-term hospital treatment, S. aureus, P. aeruginosa, Enterococcus spp. and Escherichia coli are often the causative agents of skin infections. In localized, uncomplicated superficial pyoderma, local therapy is most often used. Dioxidin® is a derivative of di-N-oxy quinoxaline, a synetic broad-spectrum bactericidal drug that has been actively used by otolaryngologists and surgeons since 1976 to combat various bacterial infections. The drug is produced in the form of an aqueous solution for intravenous and intracavitary administration, as well as in the form of new dosage forms for topical and external use. Dioxidin is characterized by high bactericidal activity against a wide range of microorganisms, including anaerobic ones, and also acts against Candida albicans. This drug is able to completely suppress microorganisms with acquired resistance to antimicrobial drugs of other classes, including multiresistant strains. Dioxidine® in a new dosage form (0.25 mg/ml solution for topical and external use) has shown high efficacy when applied cutaneous to superficial pyoderma.